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Abstract
AIM: To study the prevalence, predictors and control
of bleeding following N-butyl 2 cyanoacrylate (NBC)
sclerotherapy of gastric varix (GV).
METHODS: We analyzed case records of 1436 patients
with portal hypertension, who underwent endoscopy
during the past five years for variceal screening or
upper gastrointestinal (GI) bleeding. Fifty patients with
bleeding GV underwent sclerotherapy with a mean of
2 mL NBC for control of bleeding. Outcome parameters
were primary hemostasis (bleeding control within the
first 48 h), recurrent bleeding (after 48 h of esophagogastro-duodenoscopy) and in-hospital mortality were
analyzed.
RESULTS: The prevalence of GV in patients with portal
hypertension was 15% (220/1436) and the incidence of
bleeding was 22.7% (50/220). Out of the 50 bleeding
GV patients, isolated gastric varices (IGV-I) were seen in
22 (44%), gastro-oesophageal varices (GOV) on lesser
curvature (GOV-Ⅰ) in 16 (32%), and GOV on greater
curvature (GOV-Ⅱ) in 15 (30%). IGV-Ⅰ was seen in
44% (22/50) patients who had bleeding as compared
to 23% (39/170) who did not have bleeding (P <
0.003). Primary hemostasis was achieved with NBC in
all patients. Re-bleeding occurred in 7 (14%) patients
after 48 h of initial sclerotherapy. Secondary hemostasis
was achieved with repeat NBC sclerotherapy in 4/7
(57%). Three patients died after repeat sclerotherapy,
one during transjugular intrahepatic portosystemic
stem shunt (TIPSS), one during surgery and one due to
uncontrolled bleeding. Treatment failure-related mortality
rate was 6% (3/50).
CONCLUSION: GV can be seen in 15% of patients with

portal hypertension and the incidence of bleeding is
22.7%. NBC is highly effective in controlling GV bleeding.
In hospital mortality of patients with bleeding GV is 6%.
© 2007 The WJG Press. All rights reserved.
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INTRODUCTION
Gastric varix (GV) and its association with portal
hypertension were first described in 1913[1]. Since then,
there have been reports on different aspects of gastric
varices including prevalence, bleed tendency and treatment
options. The prevalence of GV in patients with portal
hypertension varies from 18% to 70%[2,3], although the
incidence of bleeding from gastric varices is relatively low
ranging from 10% to 36%[3].
Management of GV presents is a challenging problem,
because (1) since there is no consensus regarding the
optimum treatment of GV, treatment tends to be empiric;
(2) GV is not a homogeneous entity, and accurate
classification defines its natural history and dictates its
management; (3) although GV bleeding occurs less
frequently than esophageal varix (EV) bleeding [4,5] ,
whenever bleeding occurs it tends to be more severe
and requires more red blood cell transfusions and has a
higher mortality than EV bleeding[5]; (4) after control of
acute bleeding, GV has a high rebleeding rate of 34% to
89%[6]; and (5) there is no consensus regarding subsequent
sclerotherapy for prophylaxis against recurrent bleeding
in GV patients. Optimal management of GV requires a
multidisciplinary approach and close cooperation between
gastroenterologists, interventional radiologists and the
surgical team.
Sohendra et al[7] first reported in 1986 that bleeding
from gastric varices could be controlled by sclerotherapy
www.wjgnet.com
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using the tissue adhesive agent butyl cyanoacrylate.
Since then several authors have used different sclerosing
agents to achieve hemostasis in bleeding gastric varices,
including N-butyl-2 cyanoacrylate (histoacryl)[4,8], 2-octyl
cyanoacrylate[9], ethanolamine oleate injection[10], gastric
variceal banding [11] , thrombin [12] , sodium tetradecyl
sulfate[13]. However, N-butyl 2 cyanoacrylate (NBC) is the
only promising agent.
Most reports on endoscopic treatment of bleeding
gastric varices are small series, case reports, or retrospective
reviews[14,15]. Not more than 1000 patients with bleeding
GV have been treated with different sclerosing and
coagulating agents. Cyanoacrylate injection can achieve
primary hemostasis in 70% to 95% of patients with
acute GV bleeding, with an early rebleeding rate ranging
from 0% to 28% within 48 h [5,7,16]. Different doses of
cyanoacrylate are used by different gastroenterologis
ts [16,17]. Moreover, dilution ratio of NBC to lipoidal is
different[18,19]. However, there is no consensus regarding
effective dose and dilution of sclerosing agents.
This study was to analyze patients with GV in order to
establish predictors of bleeding GV, and the efficacy and
safety of NBC in treatment of bleeding GV.

MATERIALS AND METHODS
From March 2000 to March 2005, 1036 patients with
portal hypertension underwent endoscopy in our hospital.
Out of 220 GV patients with or without esophageal
varices, 50 had active bleeding gastric varices which were
treated with N-Butyl cyanoacrylate injection.
The cause of portal hypertension was defined on the
basis of ultrasound and/or computed tomographic scan
of abdomen along with Doppler ultrasound to study the
patency and spleno-portal axis in all patients with bleeding
GV.
The location of gastric varices was deter mined
according to the classification described by Sarin and
Kumar[3] and divided into gastroesophageal varices type
1 (GOV-1) GV continuing as an extension of esophageal
varices on the lesser curve of the stomach), gastroesophageal varices type 2 (GOV-2) on the greater curvature
or fundal varices communicating with esophageal varices.
Isolated gastric varices type 1 (IGV-1) and fundal varices
within a few centimeters of the gastric cardia, or isolated
gastric varices type 2 (IGV-2) and isolated ectopic gastric
varices. Active bleeding was defined as bleeding or oozing
of blood from a gastric varix, a clot or blackish ulcer or
rent over a gastric varix, or the presence of distinct large
gastric varices and absence of esophageal varices or other
cause of gastrointestinal (GI) bleeding.
The clinical characteristics of patients including age,
gender, Child-Pugh classification, type of varix, etiology
and complications in patient with gastric varices were
recorded and compared between groups with or without
bleeding (Table 1).
Endoscopic sclerotherapy with n-butyl cyanoacrylate
and lipoidal injection was performed by experienced
endoscopists using a GIFQ160 gastroscope (Olympus,
Tokyo, Japan). The sclerosant was injected into bleeding
gastric varices using the 23 G disposable needle injector
www.wjgnet.com
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Table 1 Clinical characteristics of patients with gastric varices
Characteristics

n

(%)

Number of patients
Male:Female
Mean age (yr)
Etiology of GV
HCV cirrhosis
HBV cirrhosis
NBNC
NCPHTN
Alcoholism
Budd-Chiari syndrome
Wilson’s disease
Child-Pugh classification
(A/B/C)
Types of gastric varices
GOV-1
GOV-2
IGV-1
IGV-2
GOV-1 + GOV-2
GOV-2 + IGV-2
GOV 1+IGV 2
GOV 1 + IGV 1

220
141:79
50 ± 11

(65:35)

155
38
27
9
5
1
1

(70)
(17.5)
(12.5)

39/109/72

(18/49/33)

78
56
59
6
14
3
2
2

(35)
(25)
(27)
(03)
(06)
(1.5)
(01)
(01)

(Wilson Cook Medical Inc., Winston-Salem, NC).
T he injection needle was primed with lipoidal
(approximately 0.5 mL) to fill the dead space within
the injection catheter. After the gastric varix lumen was
punctured with the needle, 2 mL of NBC (histoacryl
100%) in aliquots of 1 mL, diluted in 0.5 mL lipoidal, was
injected over 45-90 s, thus a dilution of 2:1 was achieved in
all cases (Figure 1 and Figure 2). Distilled water was used
to flush the injection needle before and after sclerotherapy.
Additional NBC was not injected if bleeding was
immediately controlled in patients. All patients received
octreotide infusion (50 mg/per hour) at admission and
continued for 3 d. All patients were given a proton pump
inhibitor, initially intravenously for 48 h and then orally for
4-6 wk as per our endoscopy unit protocol.
Outcome measures
Primary hemostasis was defined as stability of vital
clinical signs, no drop in hemoglobin concentration and
no recurrent bleeding within the first 48 h after the initial
sclerotherapy[16]. Re-bleeding was defined as hematemesis
and/or melena, hypotension (a drop in systolic blood
pressure of > 20 mmHg from baseline), fall in 2 gm/dL
of hemoglobin and/or transfusion requirement of ≥ 2
units of packed red cells within that time.
Data analysis
Statistical interpretation of data was performed using
Statistical Program for Social Sciences (SPSS) version 13.
Results were expressed as mean ± SD for all continuous
variables (e.g., age, gender, hospital stay, units of packed
cells etc.) and numbers (percentage) for categorical data
(e.g., gender, Child’s class, etc.). Analysis was performed by
using the independent t-test, chi-square test and Fisher’s
exact test wherever appropriate. P < 0.05 was considered
statistically significant.

Mumtaz K et al . NBC for bleeding gastric varices

Figure 1 Isolated gastric varices with a nipple suggesting recent bleeding.
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Figure 2 Injector needle with N- butyl cyanoacrylate in a large gastric fundal varix.

Table 2 Comparison between bleeding and non bleeding varices

Figure 3 X-ray showing N-butylcyanoacrylate deposition in a gastric varix after
sclerotherapy.

RESULTS
The prevalence of bleeding gastric varices in patients
with portal hypertension was 15% (220/1436) and the
incidence of bleeding was 22.7% (50/220). The mean age
of our patients with gastric varices was 50 ± 11 years, male
patients accounting for 65% (141). The main etiology of
bleeding gastric varices was hepatitis C-related cirrhosis in
34 (68%), followed by hepatitis B virus in 6 and non B non
C cirrhosis in 6 (12%) patients, respectively. Alcoholic liver
disease was found in 2 patients (4%), non cirrhotic portal
hypertension in 1 patient and Wilson’s disease in 1 patient,
respectively. Twelve patients (24%) belonged to ChildPugh A, 26 (52%) to Child-Pugh B, and 12 (24%) to ChildPugh C.
Out of the 50 bleeding GV patients, IGV-Ⅰwas seen
in 22 patients (44%), GOV-Ⅰin 16 patients (32%), and
GOV-Ⅱ in 15 patients (30%), concomitant GOV-Ⅰwith
GOV-Ⅱ in 3 patients. N-butyl cyanoacrylate (2 mL diluted
in 1 cc lipoidal) was injected intravariceally in all patients
with bleeding GV. The characteristics of bleeding and non
bleeding gastric varices are shown in Table 2.
Among these 50 patients, 43 (86%) had active bleeding
and 7 (14%) showed evidence of recent bleeding. Most
varices (n = 48) were large (F3) according to Hashizume
classification[20]. We compared bleeding and non bleeding
GV and found that IGV-Ⅰwas seen in 22/50 (44%)
patients who had bleeding and in 39/170 patients (23%)

Characteristics

Bleeding GV
n (%)

Age
Gender
Male
Female
Child Pugh class.
A
B
C
Type of GV
GOV-Ⅰ
GOV-Ⅱ
IGV-Ⅰ
IGV-II
Etiology of PHTN
HBV
HCV
NBNC
Alcoholic
Non cirrhotic PHTN
Wilson’s disease

50.48 ± 11.2

Non bleeding GV
n (%)
47.52 ± 12.7

P
0.14

30 (60)
20 (40)

111 (65.3)
59 (34.7)

12 (24)
26 (52)
12 (24)

27 (15.9)
83 (48.8)
60 (35.3)

0.22

16 (32)
15 (30)
22 (44)
0 (0)

77 (45.3)
58 (34.1)
39 (22.9)
11 (6.5)

0.09
0.58
< 0.01
0.06

6 (12)
34 (68)
6 (12)
02 (2)
01 (2)
01 (2)

29 (17.1)
121 (71.2)
21 (12.4)
03 (1.8)
08 (4.7)
00 (0)

0.49

0.39
0.76
0.94
0.48
0.59
0.06

patients who did not have bleeding (P < 0.003). Similarly,
IGV-Ⅱ was observed in 0/50 (0%) and 11/170 (6.4%),
GOV-Ⅰin 16/50 (32%) and 77/170 patients (45.2%)
who did not have bleeding, GOV-Ⅱ in 15/50 (30%) and
50/170 patients (29.4%) who did not have bleeding from
gastric varices, respectively.
The overall success rate for achieving primar y
hemostasis with NBC was 100% without recurrent
bleeding within 48 h. A mean of 2.0 ± 0.5 cc NBC was
injected in each patient.
Re-bleeding occurred in 7 (14%) patients after 48 h.
Secondary hemostasis with repeat NBC sclerotherapy was
achieved in 4 (57%) patients. Three patients died after
repeat sclerotherapy: one during transjugular intrahepatic
portosystemic stem shunt (TIPSS), one during surgery and
one due to uncontrollable torrential bleeding. Treatment
failure-related mortality rate was 6 % (3/50).
No major side effects occurred in most patients during
and after NBC sclerotherapy. Three patients reported mild
retrosternal chest pain which subsided within the next 24 h
(Figure 3).
www.wjgnet.com
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DISCUSSION
The overall incidence of gastric varices in patients with
portal hypertension is 2%-70%[3]. Furthermore, we found
that the incidence of bleeding from gastric varices in our
patients is 22.7%, which is also similar to other reports[5].
In this study, the rate for primary hemostasis with NBC
injection is consistent with the reported rate of 90% to
97% in other studies[8,14,16,21-23]. In our study, sclerotherapy
with 2 mL NBC diluted in 1 mL lipoidal was effective in
control of bleeding in all our patients during the first 48 h.
We used a higher dose of NBC with 2:1 dilution.
Our technique avoids dilution of NBC, thus decreasing
chances of migration and embolization as instantaneous
polymerization is delayed.
It was reported that a hemostasis rate of 95% can be
achieved without dilution of NBC, but serious side effects
such as embolization may occur[24].
The risk of embolization increases with over dilution
of cyanoacrylate which can slow down the process of
polymerization. We avoided this problem by diluting 2 mL
of NBC in 1 mL of lipoidal which was injected slowly
over 45-90 s. Although the volume of injection was large,
the side effects of a large volume were avoided and good
hemostais was achieved by keeping a balanced dilution.
We also studied the predictors of the first gastric
variceal bleeding, showing that the increased risk of
bleeding is associated with larger varices including
predominant IGV-Ⅰand GOV-Ⅰ[5]. Kim et al [23] found
that advanced Child-Pugh class and varix > 5 mm in size
are associated with an increased risk of bleeding. Unlike
esophageal varices, a high porto-systemic pressure > 12
mmHg does not cause GV bleeding, which is probably
related to the high frequency of spontaneous gastro-renal
shunts[17].
Cyanoacrylate therapy can improve and control rebleeding. The high mortality rate is primarily a reflection
of underlying advanced liver disease unaffected by the
injection of cyanoacrylate[25,26]. This is further explained by
a study of Kim et al[23] in which they prospectively followed
a cohort of patients with gastric varices who did not
undergo endoscopic therapy and found that the mortality
rate is 35% over a median of 15 mo. Therefore, the role
and efficacy of sclerotherapy for prophylaxis against
recurrent bleeding are questionable.
In the present study, re-bleeding occurred after 48 h
in 7 (14%) patients and was controllable in 4 (57%) with
repeat injection of NBC. It was reported that the incidence
of re-bleeding ranges from 23% to 35%[8,10,16]. However,
Kind et al[14] reported that the incidence of re-bleeding is
15.5%.
Treatment failure-related mortality in our study was
6%, which is consistent with the reported mortality [16].
Another study showed that the mortality is 12.5% due to
re-bleeding immediately after NBC sclerotherapy[8]. Kind
et al[14] reported that the hospital mortality rate is 19.5% in
patients with bleeding gastric varices.
In conclusion, endoscopic injection of NBC at a
dilution of 2:1 appears to be effective and safe for the
control of hemostasis in patients with bleeding gastric
varices. If NBC is injected slowly, a large amount of
www.wjgnet.com
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NBC in proper dilution can be used without serious side
effects.
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